Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (1349.HK)
HKD 2.43
(-0.82%)
HKD 2.43
(-0.82%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.17 Billion CNY | -1.21% |
| 2022 | -1.16 Billion CNY | 1.11% |
| 2021 | -1.17 Billion CNY | 14.49% |
| 2020 | -1.37 Billion CNY | -226.58% |
| 2019 | -421.7 Million CNY | 3.77% |
| 2018 | -438.22 Million CNY | -33.55% |
| 2017 | -328.14 Million CNY | 16.14% |
| 2016 | -391.28 Million CNY | -21.9% |
| 2015 | -320.99 Million CNY | 3.05% |
| 2014 | -331.09 Million CNY | -16.2% |
| 2013 | -284.92 Million CNY | -796.87% |
| 2012 | -31.76 Million CNY | -0.03% |
| 2011 | -31.75 Million CNY | -83.31% |
| 2010 | -17.32 Million CNY | 22.13% |
| 2009 | -22.24 Million CNY | -774.39% |
| 2008 | 3.29 Million CNY | -79.85% |
| 2007 | 16.37 Million CNY | 167.7% |
| 2006 | -24.18 Million CNY | 51.4% |
| 2005 | -49.75 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -1.22 Billion CNY | -3.81% |
| 2024 Q2 | -1.21 Billion CNY | 1.08% |
| 2023 FY | -1.17 Billion CNY | -1.21% |
| 2023 Q2 | -1.11 Billion CNY | -43.73% |
| 2023 Q1 | -773.54 Million CNY | 33.57% |
| 2023 Q3 | -1.13 Billion CNY | -1.82% |
| 2023 Q4 | -1.17 Billion CNY | -4.11% |
| 2022 Q4 | -1.16 Billion CNY | 4.54% |
| 2022 FY | -1.16 Billion CNY | 1.11% |
| 2022 Q3 | -1.21 Billion CNY | -3.55% |
| 2022 Q2 | -1.17 Billion CNY | -4.35% |
| 2022 Q1 | -1.12 Billion CNY | 4.14% |
| 2021 Q3 | -894.92 Million CNY | 18.32% |
| 2021 Q2 | -1.09 Billion CNY | 18.78% |
| 2021 FY | -1.17 Billion CNY | 14.49% |
| 2021 Q1 | -1.34 Billion CNY | 2.05% |
| 2021 Q4 | -1.17 Billion CNY | -31.59% |
| 2020 Q1 | -384.01 Million CNY | 8.94% |
| 2020 Q2 | -1.36 Billion CNY | -255.17% |
| 2020 Q3 | -1.3 Billion CNY | 4.65% |
| 2020 Q4 | -1.37 Billion CNY | -5.9% |
| 2020 FY | -1.37 Billion CNY | -226.58% |
| 2019 Q1 | 588.22 Million CNY | 234.23% |
| 2019 Q2 | -341.03 Million CNY | -157.98% |
| 2019 Q4 | -421.7 Million CNY | 0.0% |
| 2019 FY | -421.7 Million CNY | 3.77% |
| 2018 Q1 | -342.83 Million CNY | -4.48% |
| 2018 Q4 | -438.22 Million CNY | 0.0% |
| 2018 Q3 | -438.22 Million CNY | -27.82% |
| 2018 FY | -438.22 Million CNY | -33.55% |
| 2018 Q2 | -342.83 Million CNY | 0.0% |
| 2017 FY | -328.14 Million CNY | 16.14% |
| 2017 Q3 | -328.14 Million CNY | 12.7% |
| 2017 Q2 | -375.89 Million CNY | 0.0% |
| 2017 Q1 | -375.89 Million CNY | 3.93% |
| 2017 Q4 | -328.14 Million CNY | 0.0% |
| 2016 Q2 | -348.24 Million CNY | 0.0% |
| 2016 Q4 | -391.28 Million CNY | 0.0% |
| 2016 FY | -391.28 Million CNY | -21.9% |
| 2016 Q1 | -348.24 Million CNY | -8.49% |
| 2016 Q3 | -391.28 Million CNY | -12.36% |
| 2015 Q3 | -320.99 Million CNY | -7.7% |
| 2015 FY | -320.99 Million CNY | 3.05% |
| 2015 Q2 | -298.05 Million CNY | 0.0% |
| 2015 Q4 | -320.99 Million CNY | 0.0% |
| 2015 Q1 | -298.05 Million CNY | 9.98% |
| 2014 FY | -331.09 Million CNY | -16.2% |
| 2014 Q4 | -331.09 Million CNY | 0.0% |
| 2014 Q3 | -331.09 Million CNY | -27.74% |
| 2014 Q2 | -259.2 Million CNY | 0.0% |
| 2014 Q1 | -259.2 Million CNY | 9.03% |
| 2013 Q2 | -196 Million CNY | -221.78% |
| 2013 Q4 | -284.92 Million CNY | 0.0% |
| 2013 FY | -284.92 Million CNY | -796.87% |
| 2013 Q1 | 160.94 Million CNY | 606.62% |
| 2012 Q2 | -3.09 Million CNY | 0.0% |
| 2012 FY | -31.76 Million CNY | -0.03% |
| 2012 Q4 | -31.76 Million CNY | 0.0% |
| 2011 FY | -31.75 Million CNY | -83.31% |
| 2011 Q2 | -38.38 Million CNY | 0.0% |
| 2011 Q4 | -31.75 Million CNY | 0.0% |
| 2010 Q2 | -59.1 Million CNY | 0.0% |
| 2010 FY | -17.32 Million CNY | 22.13% |
| 2010 Q4 | -17.32 Million CNY | 0.0% |
| 2009 FY | -22.24 Million CNY | -774.39% |
| 2008 FY | 3.29 Million CNY | -79.85% |
| 2007 FY | 16.37 Million CNY | 167.7% |
| 2006 FY | -24.18 Million CNY | 51.4% |
| 2005 FY | -49.75 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | -258.7 Million HKD | -355.586% |
| Grand Pharmaceutical Group Limited | 2.03 Billion HKD | 158.007% |
| Extrawell Pharmaceutical Holdings Limited | 5.94 Million HKD | 19928.638% |
| Wai Yuen Tong Medicine Holdings Limited | 301.53 Million HKD | 490.87% |
| Qianhai Health Holdings Limited | -19.03 Million HKD | -6090.851% |
| Lee's Pharmaceutical Holdings Limited | 30.94 Million HKD | 3908.37% |
| Essex Bio-Technology Limited | -219.22 Million HKD | -437.618% |
| Tongfang Kontafarma Holdings Limited | 256.16 Million HKD | 560.101% |
| PuraPharm Corporation Limited | 377.54 Million HKD | 412.175% |
| SSY Group Limited | 1.71 Billion HKD | 168.783% |
| JBM (Healthcare) Limited | -7.39 Million HKD | -15829.372% |
| Jacobson Pharma Corporation Limited | 337.44 Million HKD | 449.279% |
| China Resources Pharmaceutical Group Limited | 50.97 Billion HKD | 102.312% |